Compare AbbVie Inc (ABBV) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Skyworks Solutions Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Skyworks Solutions Inc trades at $58.71 (market cap $8.99B). The key difference: AbbVie Inc is far larger — about 50× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.75%). Which is the better fit depends on your goals.
| ABBV | SWKS | |
|---|---|---|
Market Cap | $449.91B | $8.99B |
Sector | Health | Technology |
52-Week High | $261.07 | $83.40 |
52-Week Low | $184.85 | $52.50 |
Enterprise Value | $513.38B | $8.76B |
Dividend Yield | 2.72% | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Skyworks Solutions (SWKS) trades at $59.76, down 4.48% on the day, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and net income margins over recent years, though profitability metrics like gross margin remain solid at 41.08%. Recent news highlights product launches in EV and AI infrastructure alongside ongoing legal investigations into corporate governance.
The outlook is mixed: strong analyst buy consensus (60%) and a $72.56 price target suggest upside, but declining cash flow and revenue trends pose risks. Investment opportunity lies in market diversification and new tech segments, balanced against margin pressure and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
